A randomised, non-comparative, multicentre, phase II, parallel-group trial of ZD1839 (Iressa) [gefitinib] in combination with 5 fluorouracil, leucovorin [folinic acid] and cpt-11 (irinotecan) in patients with metastatic colorectal cancer.

Trial Profile

A randomised, non-comparative, multicentre, phase II, parallel-group trial of ZD1839 (Iressa) [gefitinib] in combination with 5 fluorouracil, leucovorin [folinic acid] and cpt-11 (irinotecan) in patients with metastatic colorectal cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2011

At a glance

  • Drugs Fluorouracil; Folinic acid; Gefitinib; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Jan 2011 Last checked against ClinicalTrials.gov record.
    • 26 Jan 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 17 Jul 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top